Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLANI PK/Safety Study in Healthy Volunteers
NCT03810495Phase 1Completed
- Sponsor
- Go Medical Industries
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naltrexone in opioid use disorder (OUD), sponsored by Go Medical Industries. Primary endpoint: Percentage of Participants That Maintain Minimum Effective Concentration up to 540 days. Started Apr 2019; status: completed.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03810495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810495.